This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pfizer's Xalkori Gets Breakthrough Status for New Indications
by Zacks Equity Research
Pfizer's (PFE) lung cancer drug, Xalkori (crizotinib), gets Breakthrough Therapy designation by the FDA for two new indications.
Roche's Tecentriq Study Meets Co-Primary Endpoints for NSCLC
by Zacks Equity Research
Roche's (RHHBY) Tecentriq meets its co-primary endpoints of overall survival and progression-free survival in a phase III study for lung cancer.
AstraZeneca's Imfinzi Improves Survival in Lung Cancer Study
by Zacks Equity Research
AstraZeneca Plc. (AZN) announces positive overall survival (OS) data from an interim analysis of a phase III PACIFIC study evaluating its oncology candidate, Imfinzi.
Prothena Restructures Resources, to Cut Workforce by 57%
by Zacks Equity Research
Prothena announces a reduction in workforce by 57%, due to the discontinuation of lead program, NEOD001.
Allergan Stock Down Since Q1 Earnings Report: Here's Why
by Zacks Equity Research
Though Allergan (AGN) boasts a solid underlying business, its stock is down. Here we discuss why.
Roche (RHHBY) Announces Positive Data on Hemophilia Drug
by Zacks Equity Research
Roche (RHHBY) announces positive data from two phase III studies on hemophilia drug Hemlibra which has further strengthened its hemophilia portfolio.
Roche Tecentriq Combo Achieves Longer Overall Survival Rate
by Zacks Equity Research
Roche's (RHHBY) immuno-oncology drug, Tecentriq, in combination with Avastin and chemotherapies leads to significantly longer overall survival rates in treatment-naive NSCLC patients.
Exelixis' Cabometyx Gets EU Nod for First-Line Kidney Cancer
by Zacks Equity Research
European Commission approves Exelixis' (EXEL) Cabometyx 20 mg, 40 mg and 60 mg for the first-line treatment of adults with intermediate- or poor-risk renal cell carcinoma in the European Union.
Roche's Actemra Gets FDA Nod for Subcutaneous Formulation
by Zacks Equity Research
FDA approves the subcutaneous formulation of Roche's (RHHBY) Actemra for the treatment of active polyarticular juvenile idiopathic arthritis in patients two years or older.
Pharma Stock Roundup: LLY to Buy Cancer Biotech, J&J, AZN, Roche Announce Updates
by Zacks Equity Research
Lilly signs deal to buy immuno-oncology biotech ARMO Biosciences for about $1.6 billion. J&J's Darzalex gains FDA approval in first-line setting.
Inovio's (INO) Q1 Loss Wider than Expected, Shares Down
by Zacks Equity Research
Inovio (INO) reports wider-than-expected loss and revenues miss estimates in the first quarter of 2018.
Ophthotech's (OPHT) Q1 Loss Narrows Y/Y, Zimura in Focus
by Zacks Equity Research
Ophthotech (OPHT) reports narrower year-over-year loss for the first quarter.
Horizon Pharma (HZNP) Q1 Earnings & Sales Miss, Shares Fall
by Zacks Equity Research
Horizon Pharma (HZNP) misses earnings and sales estimates in Q1. However, the orphan unit and the rheumatology business continue to grow.
Puma Biotech (PBYI) Q1 Loss Narrows, Sales Miss, Stock Down
by Zacks Equity Research
Puma Biotechnology (PBYI) Q1 loss per share is narrower than the Zacks Consensus Estimate while sales misses the same.
Mylan (MYL) Q1 Earnings Lag on Weak North America Sales
by Ekta Bagri
Mylan's first-quarter results were dismal with both earnings and sales missing expectations as challenges in North America persist.
Epizyme (EPZM) Reports Narrower-Than-Expected Loss in Q1
by Zacks Equity Research
Epizyme (EPZM) betters loss estimates in Q1 and expects to file a new drug application to the FDA for its lead pipeline candidate tazemetostat in fourth-quarter 2018.
Prothena (PRTA) Q1 Loss Wider Than Expected, Sales Miss
by Zacks Equity Research
Prothena's (PRTA) wider-than-expected loss in the first quarter was disappointing. Sales also missed estimates by a huge margin.
Is a Beat in Store for Epizyme (EPZM) This Earnings Season?
by Zacks Equity Research
Epizyme (EPZM) is expected to provide updates on pipeline candidates when it reports Q1 results on May 8.
ImmunoGen (IMGN) Q1 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
ImmunoGen (IMGN) reports wider-than-expected loss in Q1. Lower license and milestone fees resulted in substantial decrease in year-over-revenues.
What's in Store for Prothena (PRTA) This Earnings Season?
by Zacks Equity Research
Prothena (PRTA) has faced quite a few setbacks in the year so far and hence investors will be focused on management's strategy when it reports first-quarter results next week.
Exelixis (EXEL) Q1 Earnings & Sales Top on Cabometyx Strength
by Zacks Equity Research
Exelixis (EXEL) posted a strong performance in the first-quarter as lead drug Cabometyx made further inroads in the RCC market.
Can Celgene (CELG) Keep Its Earnings Streak Alive in Q1?
by Zacks Equity Research
Celgene (CELG) is likely to maintain momentum in the first quarter on the strength of its lead drug, Revlimid despite recent failures.
What's in Store for ImmunoGen (IMGN) This Earnings Season?
by Zacks Equity Research
ImmunoGen's (IMGN) considerable progress with lead pipeline candidate, mirvetuximab soravtansine, might drive the stock in Q1.
Is a Beat in the Cards for Exelixis (EXEL) in Q1 Earnings?
by Zacks Equity Research
Exelixis is likely to beat on earnings when it reports first-quarter results (May 2) driven by strong growth of Cabometyx sales.
Roche (RHHBY) Q1 Earnings: Ocrevus, Perjeta Drive Sales Beat
by Zacks Equity Research
Roche (RHHBY) beat sales estimates in the first quarter driven by strong performance of Ocrevus and Perjeta which offset the legacy sales decline.